• Home

  • Documents

  • Assessment report - European Medicines Agency · Assessment report . Blitzima . International...

If you can't read please download the document

Assessment report - European Medicines Agency · Assessment report . Blitzima . International non-proprietary name: rituximab . Procedure No. EMEA/H/C/004723/0000 . Note . Assessment

  • Upload
    others

  • View
    0

  • Download
    0

Embed Size (px)

RITUXIMAB (RITUXAN , RUXIENCE & TRUXIMARituxan® (rituximab) ®Rituxan Hycela (rituximab and hyaluronidase human)* Ruxience (rituximab-pvvr ... Multiple sclerosis (MS)69,70,113-116

RITUXIMAB (RITUXAN , RUXIENCE & TRUXIMARituxan® (rituximab) ®Rituxan Hycela (rituximab and hyaluronidase human)* Ruxience (rituximab-pvvr ... Multiple sclerosis (MS)69,70,113-116

Documents
Genentech, Inc. Rituximab SC (rituximab/hyaluronidase) BLA ... · Genentech, Inc. Rituximab SC (rituximab/hyaluronidase) BLA 761064 . ADVISORY COMMITTEE BRIEFING MATERIALS Available

Genentech, Inc. Rituximab SC (rituximab/hyaluronidase) BLA ... · Genentech, Inc. Rituximab SC (rituximab/hyaluronidase) BLA 761064 . ADVISORY COMMITTEE BRIEFING MATERIALS Available

Documents
NEW ZEALAND DATA SHEET MabThera (rituximab)

NEW ZEALAND DATA SHEET MabThera (rituximab)

Documents
Rituximab in Chronic Lymphocytic Leukemia

Rituximab in Chronic Lymphocytic Leukemia

Documents
REGENERATION LYMPHOCYTAIRE B POST-RITUXIMAB DANS …

REGENERATION LYMPHOCYTAIRE B POST-RITUXIMAB DANS …

Documents
Successful practice changing development plans: Rituximab ... · Rituximab may have unexpected/severe toxicity in children Two rituximab phase 2 trials in children ... protocol APR2010

Successful practice changing development plans: Rituximab ... · Rituximab may have unexpected/severe toxicity in children Two rituximab phase 2 trials in children ... protocol APR2010

Documents
Australian Public Assessment Report for Rituximab · Australian Public Assessment Report for Rituximab ... Roche Products Pty ... published as papers in peer-reviewed journals or

Australian Public Assessment Report for Rituximab · Australian Public Assessment Report for Rituximab ... Roche Products Pty ... published as papers in peer-reviewed journals or

Documents
CP.PHAR.260 Rituximab (Rituxan), Rituximab-pvvr (Ruxience), Rituximab-abbs (Truxima), Rituximab … · Rituximab, Rituximab-pvvr, Rituximab-abbs, Rituximab-Hyaluronidase Page 4 of

CP.PHAR.260 Rituximab (Rituxan), Rituximab-pvvr (Ruxience), Rituximab-abbs (Truxima), Rituximab … · Rituximab, Rituximab-pvvr, Rituximab-abbs, Rituximab-Hyaluronidase Page 4 of

Documents
Rituximab in Nephrology · Rituximab in Nephrology Dr F. Moeinzadeh and polymyositis 12/7/1397 4. Clinical use of rituximab in renal transplantation Induction Desensitization in antibody

Rituximab in Nephrology · Rituximab in Nephrology Dr F. Moeinzadeh and polymyositis 12/7/1397 4. Clinical use of rituximab in renal transplantation Induction Desensitization in antibody

Documents
WITHDRAWAL ASSESSMENT REPORT FOR Garenoxac in ......Doc. Ref: EMEA/CHMP/363573/2007 WITHDRAWAL ASSESSMENT REPORT FOR in Mesylate (garenoxacin) London, 1 Garenoxac EMEA/H/C/747 Day

WITHDRAWAL ASSESSMENT REPORT FOR Garenoxac in ......Doc. Ref: EMEA/CHMP/363573/2007 WITHDRAWAL ASSESSMENT REPORT FOR in Mesylate (garenoxacin) London, 1 Garenoxac EMEA/H/C/747 Day

Documents
Uses of Rituximab in Nephrology

Uses of Rituximab in Nephrology

Health & Medicine
WITHDRAWAL ASSESSMENT REPORT THERALOC · Doc. Ref: EMEA/67305/2009 WITHDRAWAL ASSESSMENT REPORT FOR THERALOC International Nonproprietary Name: nimotuzumab Procedure No. EMEA/H/C/931

WITHDRAWAL ASSESSMENT REPORT THERALOC · Doc. Ref: EMEA/67305/2009 WITHDRAWAL ASSESSMENT REPORT FOR THERALOC International Nonproprietary Name: nimotuzumab Procedure No. EMEA/H/C/931

Documents
Severe Colitis Induced by Rituximab - Albany … Colitis Induced by Rituximab Zachary Feinberg MD1 ... Infectious Disease Center3; Department of Neurology4, Albany, New York Rituximab,

Severe Colitis Induced by Rituximab - Albany … Colitis Induced by Rituximab Zachary Feinberg MD1 ... Infectious Disease Center3; Department of Neurology4, Albany, New York Rituximab,

Documents
5.01.556 Rituximab: Non-oncologic and Miscellaneous UsesLupus nephritis Rituxan® (rituximab) OR Ruxience™ (rituximab-pvvr) may be considered medically necessary as first line products

5.01.556 Rituximab: Non-oncologic and Miscellaneous UsesLupus nephritis Rituxan® (rituximab) OR Ruxience™ (rituximab-pvvr) may be considered medically necessary as first line products

Documents
Assessment Report For MabThera (rituximab) … · recommended for patients ... two-arm study comparing rituximab maintenance with observation, ... number of immunochemotherapy cycles

Assessment Report For MabThera (rituximab) … · recommended for patients ... two-arm study comparing rituximab maintenance with observation, ... number of immunochemotherapy cycles

Documents
CVMP assessment report for Forceris (EMEA/V/C/004329/0000)€¦ · CVMP assessment report for Forceris (EMEA/V/C/004329/0000) EMA/138662/2019 Page 5/37 Part 1 - Administrative particulars

CVMP assessment report for Forceris (EMEA/V/C/004329/0000)€¦ · CVMP assessment report for Forceris (EMEA/V/C/004329/0000) EMA/138662/2019 Page 5/37 Part 1 - Administrative particulars

Documents
Withdrawal assessment report for Oncept Melanoma (EMEA/V/C

Withdrawal assessment report for Oncept Melanoma (EMEA/V/C

Documents
(*riTUXimab) Cyclophosphamide, DOXOrubicin, vinCRIStine

(*riTUXimab) Cyclophosphamide, DOXOrubicin, vinCRIStine

Documents
Cladribine + Rituximab in HCL : UPDATE

Cladribine + Rituximab in HCL : UPDATE

Documents
Cetuximab and Rituximab

Cetuximab and Rituximab

Documents
Rituximab and Hyaluronidase injection, for subcutaneous use · 1 Rituximab and Hyaluronidase injection, for subcutaneous use (rituximab SC) BLA 761064 R. Angelo de Claro, MD Medical

Rituximab and Hyaluronidase injection, for subcutaneous use · 1 Rituximab and Hyaluronidase injection, for subcutaneous use (rituximab SC) BLA 761064 R. Angelo de Claro, MD Medical

Documents
CVMP assessment report for UBAC (EMEA/V/C/004595/0000) · CVMP assessment report for UBAC (EMEA/V/C/004595/0000) EMA/368039/2018 Page 4/30 Introduction The applicant Laboratorios

CVMP assessment report for UBAC (EMEA/V/C/004595/0000) · CVMP assessment report for UBAC (EMEA/V/C/004595/0000) EMA/368039/2018 Page 4/30 Introduction The applicant Laboratorios

Documents
Targeted Therapy with Rituximab in Felty’s Syndrome: A ... of Felty’s Syndrome with Rituximab The Open Rheumatology Journal, 2012, Volume 6 313 and a treatment with rituximab was

Targeted Therapy with Rituximab in Felty’s Syndrome: A ... of Felty’s Syndrome with Rituximab The Open Rheumatology Journal, 2012, Volume 6 313 and a treatment with rituximab was

Documents
Rituximab in Minimal Change

Rituximab in Minimal Change

Health & Medicine
Integrated Impact Assessment Report for Clinical ... · Integrated Impact Assessment Report for Clinical Commissioning Policies Policy Reference Number 1625 Policy Title Rituximab

Integrated Impact Assessment Report for Clinical ... · Integrated Impact Assessment Report for Clinical Commissioning Policies Policy Reference Number 1625 Policy Title Rituximab

Documents
Rituxan (rituximab)

Rituxan (rituximab)

Documents
Rituximab Biosimilar Brochure

Rituximab Biosimilar Brochure

Health & Medicine
CVMP assessment report for Baycox Iron (EMEA/V/C/004794/0000) › en › documents › assessment-report › ... · CVMP assessment report for Baycox Iron (EMEA/V/C/004794/0000) EMA/193625/2019

CVMP assessment report for Baycox Iron (EMEA/V/C/004794/0000) › en › documents › assessment-report › ... · CVMP assessment report for Baycox Iron (EMEA/V/C/004794/0000) EMA/193625/2019

Documents
Rituximab efficacy in other haematological malignancies

Rituximab efficacy in other haematological malignancies

Documents
Australian public assessment for Rituximab · Web viewThis AusPAR describes the application by the sponsor to register an alternative, faster (2 h) infusion schedule of MabThera (rituximab)

Australian public assessment for Rituximab · Web viewThis AusPAR describes the application by the sponsor to register an alternative, faster (2 h) infusion schedule of MabThera (rituximab)

Documents